Prognostic and Monitoring Utility of Serum CEA in Lung Adenocarcinoma: Differential Roles in EGFR‐TKI and Chemotherapy Treatments
Cancer Medicine · 2025
DOI: 10.1002/cam4.71170 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Medicine, 2025. Verfasst von Yen-Shou Kuo und 4 weiteren Autor:innen. Beteiligte Einrichtung: Division of Thoracic Surgery, Department of Surgery, Tri-Service General Hospital, National Defense Medical University, Taipei, Taiwan. Hauptthemen laut MEDLINE: Adenocarcinoma of Lung, Carcinoembryonic Antigen, Lung Neoplasms, Protein Kinase Inhibitors. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 56 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Tri-Service General Hospital, National Science and Technology Council, Taiwan, National Science and Technology Council.
Themen: Onkologische Pflege
Abstract (Originalsprache)
Background
Serum carcinoembryonic antigen (CEA) has potential prognostic and monitoring significance in lung adenocarcinoma (LUAD) patients undergoing different treatments, such as epidermal growth factor receptor (EGFR)‐tyrosine kinase inhibitors (TKIs) and chemotherapy. The changes in CEA expression during relapses, influenced by resistance mechanisms involving cytokines and epigenetic factors, may impact its utility in disease prognosis, monitoring, and management.
Methods
This retrospective study analyzed advanced LUAD patients treated between 2011 and 2018, including 182 patients receiving EGFR‐TKIs and 102 undergoing chemotherapies. Serum CEA levels were measured at baseline and relapse. Associations between CEA levels, treatment modalities, and survival outcomes were assessed using Cox regression and Kaplan–Meier analyses. Gene expression profiling and in vitro experiments explored the regulation of CEACAM5 expression by cytokines and epigenetic mechanisms in EGFR‐TKI‐resistant cells.
Results
Elevated baseline CEA (≥ 5 ng/mL) was associated with significantly worse overall survival (OS) in patients treated with EGFR‐TKIs but showed no prognostic value in chemotherapy‐treated patients. During the relapse, EGFR‐TKI–treated patients were more likely to exhibit a transition to CEA‐negative status (< 5 ng/mL) compared to those receiving chemotherapy. Mechanistic studies revealed that EGFR‐TKI‐resistant cells displayed reduced CEACAM5 expression and increased epithelial‐to‐mesenchymal transition (EMT) markers, driven by cytokine signaling and epigenetic modifications.
Conclusions
Serum CEA is a stronger prognostic biomarker for LUAD patients treated with EGFR‐TKIs while offering consistent monitoring capabilities in chemotherapy‐treated patients. These findings highlight the differential clinical value of serum CEA in guiding therapeutic strategies and monitoring disease progression across treatment modalities.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Thoracic Surgery, Department of Surgery, Tri-Service General Hospital, National Defense Medical University, Taipei, Taiwan.
- Institute of Biotechnology, National Tsing Hua University, Hsinchu, Taiwan.
- Department of Dentistry, Tri-Service General Hospital, Taipei, Taiwan.
- National Defense Medical University, Taipei, Taiwan.
ORCID-Profile: Yu-Ting Chou
Förderung
- Tri-Service General Hospital
- National Science and Technology Council, Taiwan
- National Science and Technology Council
Zitieren
APA
Kuo, Y. S., Zheng, M. Y., Shieh, Y. S., Huang, T. W., & Chou, Y. T. (2025). Prognostic and Monitoring Utility of Serum CEA in Lung Adenocarcinoma: Differential Roles in EGFR‐TKI and Chemotherapy Treatments. Cancer Medicine. https://doi.org/10.1002/cam4.71170
Vancouver
Kuo YS, Zheng MY, Shieh YS, Huang TW, Chou YT. Prognostic and Monitoring Utility of Serum CEA in Lung Adenocarcinoma: Differential Roles in EGFR‐TKI and Chemotherapy Treatments. Cancer Medicine. 2025. doi:10.1002/cam4.71170
BibTeX
@article{Kuo2025,
author = {Kuo, Yen-Shou and Zheng, Ming-Yi and Shieh, Yi-Shing and Huang, Tsai-Wang and Chou, Yu-Ting},
title = {Prognostic and Monitoring Utility of Serum CEA in Lung Adenocarcinoma: Differential Roles in EGFR‐TKI and Chemotherapy Treatments},
journal = {Cancer Medicine},
year = {2025},
doi = {10.1002/cam4.71170}
}
EUVIMED